ES3014068T3 - Nalmefene for reduction of alcohol consumption in specific target populations - Google Patents

Nalmefene for reduction of alcohol consumption in specific target populations Download PDF

Info

Publication number
ES3014068T3
ES3014068T3 ES23163177T ES23163177T ES3014068T3 ES 3014068 T3 ES3014068 T3 ES 3014068T3 ES 23163177 T ES23163177 T ES 23163177T ES 23163177 T ES23163177 T ES 23163177T ES 3014068 T3 ES3014068 T3 ES 3014068T3
Authority
ES
Spain
Prior art keywords
nalmefene
patient
alcohol
use according
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES23163177T
Other languages
English (en)
Spanish (es)
Inventor
Lars Torup
Afsaneh Abbariki
Anna Bladström
Christine Persson
Didier Meulien
Per Sørensen
Thomas Jensen
Jette Østergaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48703496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3014068(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Application granted granted Critical
Publication of ES3014068T3 publication Critical patent/ES3014068T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
ES23163177T 2012-06-27 2013-06-27 Nalmefene for reduction of alcohol consumption in specific target populations Active ES3014068T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261664804P 2012-06-27 2012-06-27
US201261721539P 2012-11-02 2012-11-02
US201261736740P 2012-12-13 2012-12-13
US201361788810P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
ES3014068T3 true ES3014068T3 (en) 2025-04-16

Family

ID=48703496

Family Applications (4)

Application Number Title Priority Date Filing Date
ES23163177T Active ES3014068T3 (en) 2012-06-27 2013-06-27 Nalmefene for reduction of alcohol consumption in specific target populations
ES13732471.1T Active ES2609122T3 (es) 2012-06-27 2013-06-27 Nalmefeno para la reducción del consumo de alcohol en poblaciones objetivos específicas
ES17206034T Active ES2950492T3 (es) 2012-06-27 2013-06-27 Nalmefeno para la reducción del consumo de alcohol en poblaciones objetivos específicas
ES16187426.8T Active ES2663532T3 (es) 2012-06-27 2013-06-27 Nalmefeno para la reducción del consumo de alcohol en poblaciones objetivos específicas

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES13732471.1T Active ES2609122T3 (es) 2012-06-27 2013-06-27 Nalmefeno para la reducción del consumo de alcohol en poblaciones objetivos específicas
ES17206034T Active ES2950492T3 (es) 2012-06-27 2013-06-27 Nalmefeno para la reducción del consumo de alcohol en poblaciones objetivos específicas
ES16187426.8T Active ES2663532T3 (es) 2012-06-27 2013-06-27 Nalmefeno para la reducción del consumo de alcohol en poblaciones objetivos específicas

Country Status (35)

Country Link
US (4) US20140005216A1 (enExample)
EP (5) EP3138564B1 (enExample)
JP (3) JP6258933B2 (enExample)
KR (1) KR20150023396A (enExample)
CN (1) CN104411313A (enExample)
AU (1) AU2013283281B2 (enExample)
BR (1) BR112014032555A2 (enExample)
CA (1) CA2874703C (enExample)
CL (1) CL2014003484A1 (enExample)
CO (1) CO7160087A2 (enExample)
CY (3) CY1118579T1 (enExample)
DK (3) DK3345604T3 (enExample)
EA (1) EA029908B1 (enExample)
ES (4) ES3014068T3 (enExample)
FI (1) FI3345604T3 (enExample)
HK (1) HK1255683A1 (enExample)
HR (4) HRP20230762T8 (enExample)
HU (4) HUE031110T2 (enExample)
IL (1) IL236035B (enExample)
LT (3) LT2866808T (enExample)
ME (2) ME02587B (enExample)
MX (1) MX371373B (enExample)
MY (1) MY166914A (enExample)
NZ (1) NZ702191A (enExample)
PH (1) PH12014502798A1 (enExample)
PL (4) PL3345604T3 (enExample)
PT (3) PT3138564T (enExample)
RS (2) RS55456B1 (enExample)
RU (1) RU2665373C2 (enExample)
SG (1) SG11201408704WA (enExample)
SI (3) SI2866808T1 (enExample)
SM (3) SMT201600471T1 (enExample)
UA (1) UA114199C2 (enExample)
WO (1) WO2014001427A1 (enExample)
ZA (1) ZA201409525B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
AU2015250611A1 (en) 2014-04-22 2016-11-24 H. Lundbeck A/S Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
US20170071590A1 (en) * 2015-09-10 2017-03-16 Suture Armor Llc Suture anchor
KR102699603B1 (ko) 2018-04-20 2024-08-29 삼성전자주식회사 반도체 메모리 소자

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3814768A (en) 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US20030153590A1 (en) * 2001-08-14 2003-08-14 Oy Contral Pharma Ltd Method of treating alcoholism or alcohol abuse
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
UA106752C2 (uk) 2009-05-25 2014-10-10 Х. Луннбек А/С Одержання налмефену гідрохлориду з налтрексону
EA022266B1 (ru) 2010-11-05 2015-11-30 Х. Лундбекк А/С Способ получения налтрексона
BR112013024137A2 (pt) 2011-03-31 2017-09-26 Imuneks Farma Ilac Sanayi Ve Ticaret A S composições de antagonistas de opióides e seu uso para o tratamento da esclerodermia
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations

Also Published As

Publication number Publication date
PT3138564T (pt) 2018-04-03
ZA201409525B (en) 2016-08-31
HUE070621T2 (hu) 2025-06-28
EP2866808B1 (en) 2016-11-02
CA2874703A1 (en) 2014-01-03
EP3345604A1 (en) 2018-07-11
IL236035B (en) 2018-12-31
RS57046B1 (sr) 2018-05-31
CY1126140T1 (el) 2023-11-15
EA029908B1 (ru) 2018-05-31
BR112014032555A2 (pt) 2017-06-27
PT2866808T (pt) 2017-01-03
RU2665373C2 (ru) 2018-08-29
SI2866808T1 (sl) 2017-01-31
CN104411313A (zh) 2015-03-11
JP2019163275A (ja) 2019-09-26
ES2663532T3 (es) 2018-04-13
HRP20250329T1 (hr) 2025-05-09
PL2866808T3 (pl) 2017-04-28
EP3138564B1 (en) 2018-01-31
DK2866808T3 (en) 2017-01-16
CA2874703C (en) 2022-08-23
SI3345604T1 (sl) 2023-08-31
US20180028526A1 (en) 2018-02-01
PT3345604T (pt) 2023-07-17
EP4223296A3 (en) 2023-09-27
JP2018039810A (ja) 2018-03-15
EP4541421A3 (en) 2025-06-18
US9642849B2 (en) 2017-05-09
ES2950492T3 (es) 2023-10-10
PL4223296T3 (pl) 2025-04-14
SMT201600471B (it) 2017-03-08
PL3138564T3 (pl) 2018-06-29
HRP20230762T8 (hr) 2024-01-05
SMT201800164T1 (it) 2018-07-17
US20140005216A1 (en) 2014-01-02
HRP20161717T1 (hr) 2017-02-10
MX371373B (es) 2020-01-28
HK1208185A1 (en) 2016-02-26
EP2866808A1 (en) 2015-05-06
NZ702191A (en) 2017-06-30
HUE031110T2 (en) 2017-06-28
EP4541421A2 (en) 2025-04-23
JP6258933B2 (ja) 2018-01-10
US20140005217A1 (en) 2014-01-02
AU2013283281A1 (en) 2014-12-11
SI3138564T1 (en) 2018-04-30
LT3138564T (lt) 2018-04-10
EA201492152A1 (ru) 2015-11-30
HUE063313T2 (hu) 2024-01-28
HK1255683A1 (en) 2019-08-23
DK3138564T3 (en) 2018-03-26
SMT201600471T1 (it) 2017-03-08
ME03030B (me) 2018-10-20
PH12014502798A1 (en) 2015-02-09
US20160375007A1 (en) 2016-12-29
JP2015521647A (ja) 2015-07-30
MX2014015488A (es) 2015-03-06
SG11201408704WA (en) 2015-01-29
CY1118579T1 (el) 2017-07-12
HRP20230762T1 (hr) 2023-10-13
CO7160087A2 (es) 2015-01-15
IL236035A0 (en) 2015-01-29
HRP20180363T1 (hr) 2018-04-20
DK3345604T3 (da) 2023-07-24
RU2014151156A (ru) 2016-08-20
ME02587B (me) 2017-06-20
FI3345604T3 (fi) 2023-07-28
EP4223296C0 (en) 2025-01-29
EP4223296B1 (en) 2025-01-29
CY1120097T1 (el) 2018-12-12
UA114199C2 (uk) 2017-05-10
HUE036272T2 (hu) 2018-06-28
ES2609122T3 (es) 2017-04-18
CL2014003484A1 (es) 2015-02-27
EP3138564A1 (en) 2017-03-08
AU2013283281B2 (en) 2017-04-20
LT2866808T (lt) 2017-01-10
EP4223296A2 (en) 2023-08-09
JP6857684B2 (ja) 2021-04-14
PL3345604T3 (pl) 2023-08-28
KR20150023396A (ko) 2015-03-05
WO2014001427A1 (en) 2014-01-03
MY166914A (en) 2018-07-24
LT3345604T (lt) 2023-08-10
EP3345604B1 (en) 2023-06-07
US10034874B2 (en) 2018-07-31
RS55456B1 (sr) 2017-04-28

Similar Documents

Publication Publication Date Title
JP6857684B2 (ja) 特定の標的集団におけるアルコール消費を低減するためのナルメフェン
KR20150047573A (ko) 최면 진정제의 투여 방법
RU2012133528A (ru) Способ лечения аутоиммунного демиелинизирующего заболевания центральной нервной системы (варианты)
ES2337622T3 (es) Uso de composiciones que contienen antagonistas del receptor opioide kappa para el tratamiento de trastornos disociativos.
RU2552290C1 (ru) Соединения опиоидных антагонистов и их применение при лечении склеродермии
HK1229720B (en) Nalmefene for reduction of alcohol consumption in specific target populations
HK1229720A1 (en) Nalmefene for reduction of alcohol consumption in specific target populations
HK1208185B (en) Nalmefene for reduction of alcohol consumption in specific target populations
ES3036880T3 (en) Combinations of masupirdine with donepezil or memantine for treating behavioral and psychological symptoms in patients with dementia
US20160058753A1 (en) Nalmefene for Treatment of Patients with Mood Disorder